What You Should Know:
– Phenomix Sciences, a precision medicine biotechnology company, released findings from a new survey revealing a growing demand for personalized obesity care.
– The survey of 475 patients explored attitudes toward weight management, treatment preferences, and information sources.
Key Findings:
- Patients Seek Medical Guidance: A majority of respondents (66%) prefer guidance from healthcare providers to manage weight loss, highlighting the need for a more clinical approach to obesity treatment.
- Desire for Personalized Care: Nearly two-thirds of patients expressed interest in genetic testing to tailor obesity interventions, emphasizing the growing importance of personalized medicine.
- Influence of Social Media: While social media is a primary source of information about weight loss medications like GLP-1s, only 17% of patients learned about them from healthcare providers, indicating a gap in patient education.
- Concerns About GLP-1s: Many patients have unrealistic expectations about GLP-1s, with 80% believing they will achieve significant and long-lasting weight loss. Physicians also expressed concerns about overprescription and potential negative impacts on disadvantaged groups.
These findings underscore the need for evidence-based information and personalized treatment options for obesity. Phenomix Sciences is committed to addressing these needs through its precision medicine approach.
“The results of this survey reflect a notable evolution for obesity treatment. The new obesity medications have reinforced the long overdue need to treat obesity as a disease and it’s clear patients welcome that change. However, as this transition continues, it is clear, too, that there needs to be more focus on how patients receive weight loss information and utilize available treatments backed by scientific research,” says Mark Bagnall, CEO of Phenomix Sciences.
